Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial.

AIMS: The effect of beta-blockers initiated after myocardial infarction (MI) on subsequent angina burden remains uncertain. METHODS AND RESULTS: This pre-specified BETAMI-DANBLOCK substudy included patients with MI and left ventricular ejection fraction (LVEF)≥40% randomized to beta-blockers or no beta-blockers. Endpoints comprised angina-related hospital contacts/diagnostic ischemia tests, coronary revascularization, anti-anginal medications (≥2 prescriptions for calcium-channel blockers/nitrates), and patient-reported angina symptoms [Canadian Cardiovascular Society (CCS) class 0-4]. Subdistribution hazard ratios (SHR) were estimated by Fine-Gray models. Anti-anginal prescriptions were compared using 95% confidence intervals (CI) for differences in proportions.A total of 5574 patients were randomized to beta-blockers (n=2783, median dose 50 mg metoprolol) or no beta-blockers (n=2791). During median 3.5 years follow-up, an angina-related hospital contact/diagnostic ischemia test occurred in 724 patients (26.0%) in the beta-blocker group vs. 834 (29.9%) in the no beta-blocker group (SHR 0.85; 95% CI, 0.77-0.94). Coronary revascularization occurred in 108 (3.9%) vs. 110 patients (3.9%)(SHR 0.99; 95% CI 0.76-1.29). Fewer patients in the beta-blocker group were treated with calcium-channel blockers [630(22.7%) vs. 738(26.6%); -3.9 percentage points (95% CI, -6.2 to -1.6)], whereas nitrate use [342(12.3%) vs. 356(12.8%); -0.5 (95% CI, -2.2 to 1.2)] and CCS-scores were similar between groups (difference in change at 12-months, -0.04; 95% CI, -0.14-0.05). CONCLUSIONS: In patients with MI and LVEF≥40%, a moderate dose of beta-blockers was associated with a lower incidence of first angina-related hospital contact/diagnostic ischemia testing, and lower use of calcium-channel blockers. The absence of differences in coronary revascularization, nitrate use and patient-reported angina symptoms suggests that the overall benefit on angina is limited.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/ehjcvp/pvag097
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial.

Arnhild Bakken, Therese Lucia Friis Holmager, Morten Wang Fagerland, Anna Meta Dyrvig Kristensen et al.
5 links
PubMed
Acute Myocardial Infarction Research
article

Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial.

Arnhild Bakken, Therese Lucia Friis Holmager, Morten Wang Fagerland, Anna Meta Dyrvig Kristensen, Michael Hecht Olsen, Sigrun Halvorsen, Dan Atar, Eva Prescott, John Munkhaugen, F Rykind
article en

Abstract

AIMS: The effect of beta-blockers initiated after myocardial infarction (MI) on subsequent angina burden remains uncertain. METHODS AND RESULTS: This pre-specified BETAMI-DANBLOCK substudy included patients with MI and left ventricular ejection fraction (LVEF)≥40% randomized to beta-blockers or no beta-blockers. Endpoints comprised angina-related hospital contacts/diagnostic ischemia tests, coronary revascularization, anti-anginal medications (≥2 prescriptions for calcium-channel blockers/nitrates), and patient-reported angina symptoms [Canadian Cardiovascular Society (CCS) class 0-4]. Subdistribution hazard ratios (SHR) were estimated by Fine-Gray models. Anti-anginal prescriptions were compared using 95% confidence intervals (CI) for differences in proportions.A total of 5574 patients were randomized to beta-blockers (n=2783, median dose 50 mg metoprolol) or no beta-blockers (n=2791). During median 3.5 years follow-up, an angina-related hospital contact/diagnostic ischemia test occurred in 724 patients (26.0%) in the beta-blocker group vs. 834 (29.9%) in the no beta-blocker group (SHR 0.85; 95% CI, 0.77-0.94). Coronary revascularization occurred in 108 (3.9%) vs. 110 patients (3.9%)(SHR 0.99; 95% CI 0.76-1.29). Fewer patients in the beta-blocker group were treated with calcium-channel blockers [630(22.7%) vs. 738(26.6%); -3.9 percentage points (95% CI, -6.2 to -1.6)], whereas nitrate use [342(12.3%) vs. 356(12.8%); -0.5 (95% CI, -2.2 to 1.2)] and CCS-scores were similar between groups (difference in change at 12-months, -0.04; 95% CI, -0.14-0.05). CONCLUSIONS: In patients with MI and LVEF≥40%, a moderate dose of beta-blockers was associated with a lower incidence of first angina-related hospital contact/diagnostic ischemia testing, and lower use of calcium-channel blockers. The absence of differences in coronary revascularization, nitrate use and patient-reported angina symptoms suggests that the overall benefit on angina is limited.

PubMed
University of Copenhagen (DK), Oslo University Hospital (NO), University of Oslo (NO), Drammen Hospital (NO), Vestre Viken Hospital Trust (NO), Frederiksberg Hospital (DK), Bispebjerg Hospital (DK), Copenhagen University Hospital (DK), Holbæk Sygehus (DK)
Good health and well-being
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon